The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below:

##STR00001##

wherein m, R.sub.1, n, R.sub.2 and R.sub.3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below:

##STR00001##

wherein m, R.sub.1, n, R.sub.2 and R.sub.3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.